Vicor (VICR) Q3 2026 Earnings Call Transcript

Vicor reported Q3 revenue of $197.1 million, up 37.5% sequentially and 78.5% year over year, with royalty revenue rising 119.1% sequentially to $66.6 million and gross margin reaching 68.3%. Management expects Q4 product revenue to increase about 10% sequentially and guided to at least $43 million in royalty revenue, assuming no new licensing agreements; it also cited $100 million in bookings during the first two weeks of Q4. Demand is strong, but near-term capacity constraints are prompting a phased Fab 2 expansion, with initial equipment deployment planned for Q2 2027; Fab 3 timing remains undecided.

Analysis

VICR’s key near-term constraint is not demand but its ability to convert demand into shipments: Fab 1 bottlenecks by process step cap hardware growth, while Fab 2 equipment is not expected until Q2 2027. That makes bookings and customer capacity requests less valuable than demonstrated production throughput; a fivefold capacity ambition is not yet funded or scheduled in detail, and Fab 3 remains optional. The second-order upside is strategic leverage: if VPD proves performance at point of load, VICR could gain design wins beyond its lead AI customer and make licensing relevant to a wider set of OEMs. But management’s technical claims and royalty trajectory are not independent validation. ITC investigation is leverage, not a finding of infringement or assurance of an exclusion order; adverse outcomes, delay, or design-arounds could impair the licensing thesis. The $43 million royalty floor also sits below Q3’s $66.6 million, so sequential earnings may soften even as product sales grow; royalty lumpiness and legal costs (management expects ~20% of royalties) complicate extrapolating Q3 margins. Near term, expect headline sensitivity to bookings, licenses, and the ITC path. Over 1–3 months, verify Q4 product delivery and royalty realization; over 6–18 months, watch Fab 2 ramp, customer diversification, and realized product economics. Important source-quality issue: the call transcript gives conflicting backlog figures ($46 million and nearly $400 million), while the summary says $406 million. Resolve against the 10-Q before relying on backlog as demand visibility.

Key Decisions for Investors

• Do not chase VICR solely on Q3 earnings or the reported backlog. First reconcile backlog to the 10-Q and separate firm orders from other demand indicators; the transcript’s conflicting figures materially weaken the visibility signal.
• Consider a staged, modest VICR long only after confirmation that Q4 product revenue is tracking the stated sequential-growth outlook and that royalty collections support the $43 million floor. The upside case is additional licenses and a credible Fab 2 ramp; the downside is a royalty reset, shipment delays, or failure to convert demos into additional customer programs. No valuation-based entry level is supportable from the supplied data.
• Treat the ITC process as a catalyst with binary downside, not as booked royalty growth. Reassess on procedural milestones and any indication of a preliminary or final exclusion order; a no-infringement outcome, material delay, or viable design-around would falsify the licensing upside case.
• For the next 1–3 months, track product shipments versus bookings, royalty revenue excluding catch-up payments, and legal expense as a share of royalties. For 6–18 months, track Fab 2 equipment installation and actual constrained-step output; defer underwriting the fivefold-capacity claim until management discloses capex, timing, and utilization evidence.
• Do not infer a direct trade in CBRS or INTC from the processor anecdotes: the call provides no evidence of a commercial relationship or quantified revenue exposure for either.